<?xml version='1.0' encoding='utf-8'?>
<document id="26467765"><sentence text="Local Drug-Drug Interaction of Donepezil with Cilostazol at Breast Cancer Resistance Protein (ABCG2) Increases Drug Accumulation in Heart."><entity charOffset="31-40" id="DDI-PubMed.26467765.s1.e0" text="Donepezil" /><entity charOffset="46-56" id="DDI-PubMed.26467765.s1.e1" text="Cilostazol" /><pair ddi="false" e1="DDI-PubMed.26467765.s1.e0" e2="DDI-PubMed.26467765.s1.e0" /><pair ddi="false" e1="DDI-PubMed.26467765.s1.e0" e2="DDI-PubMed.26467765.s1.e1" /></sentence><sentence text="Clinical reports indicate that cardiotoxicity due to donepezil can occur after coadministration with cilostazol"><entity charOffset="53-62" id="DDI-PubMed.26467765.s2.e0" text="donepezil" /><entity charOffset="101-111" id="DDI-PubMed.26467765.s2.e1" text="cilostazol" /><pair ddi="false" e1="DDI-PubMed.26467765.s2.e0" e2="DDI-PubMed.26467765.s2.e0" /><pair ddi="false" e1="DDI-PubMed.26467765.s2.e0" e2="DDI-PubMed.26467765.s2.e1" /></sentence><sentence text=" We speculated that the concentration of donepezil in heart tissue might be increased as a result of interaction with cilostazol at efflux transporters such as P-glycoprotein (P-gp, ABCB1) and breast cancer resistance protein (BCRP, ABCG2), which are expressed in many tissues including the heart, and our study tested this hypothesis"><entity charOffset="41-50" id="DDI-PubMed.26467765.s3.e0" text="donepezil" /><entity charOffset="118-128" id="DDI-PubMed.26467765.s3.e1" text="cilostazol" /><pair ddi="false" e1="DDI-PubMed.26467765.s3.e0" e2="DDI-PubMed.26467765.s3.e0" /><pair ddi="false" e1="DDI-PubMed.26467765.s3.e0" e2="DDI-PubMed.26467765.s3.e1" /></sentence><sentence text=" First, donepezil was confirmed to be a substrate of both BCRP and P-glycoprotein in transporter-transfected cells in vitro"><entity charOffset="8-17" id="DDI-PubMed.26467765.s4.e0" text="donepezil" /></sentence><sentence text=" Cilostazol inhibited BCRP and P-glycoprotein with half-inhibitory concentrations of 130 nM and 12"><entity charOffset="1-11" id="DDI-PubMed.26467765.s5.e0" text="Cilostazol" /></sentence><sentence text="7 Î¼M, respectively" /><sentence text=" Considering the clinically achievable unbound plasma concentration of cilostazol (about 200 nM), it is plausible that BCRP-mediated transport of donepezil would be affected by cilostazol in vivo"><entity charOffset="71-81" id="DDI-PubMed.26467765.s7.e0" text="cilostazol" /><entity charOffset="146-155" id="DDI-PubMed.26467765.s7.e1" text="donepezil" /><entity charOffset="177-187" id="DDI-PubMed.26467765.s7.e2" text="cilostazol" /><pair ddi="false" e1="DDI-PubMed.26467765.s7.e0" e2="DDI-PubMed.26467765.s7.e0" /><pair ddi="false" e1="DDI-PubMed.26467765.s7.e0" e2="DDI-PubMed.26467765.s7.e1" /><pair ddi="false" e1="DDI-PubMed.26467765.s7.e0" e2="DDI-PubMed.26467765.s7.e2" /><pair ddi="false" e1="DDI-PubMed.26467765.s7.e1" e2="DDI-PubMed.26467765.s7.e1" /><pair ddi="false" e1="DDI-PubMed.26467765.s7.e1" e2="DDI-PubMed.26467765.s7.e2" /></sentence><sentence text=" Indeed, in an in vivo rat study, we found that coadministration of cilostazol significantly increased the concentrations of donepezil in the heart and brain, where BCRP functions as a part of the blood-tissue barrier, whereas the plasma concentration of donepezil was unaffected"><entity charOffset="68-78" id="DDI-PubMed.26467765.s8.e0" text="cilostazol" /><entity charOffset="125-134" id="DDI-PubMed.26467765.s8.e1" text="donepezil" /><entity charOffset="255-264" id="DDI-PubMed.26467765.s8.e2" text="donepezil" /><pair ddi="false" e1="DDI-PubMed.26467765.s8.e0" e2="DDI-PubMed.26467765.s8.e0" /><pair ddi="false" e1="DDI-PubMed.26467765.s8.e0" e2="DDI-PubMed.26467765.s8.e1" /><pair ddi="false" e1="DDI-PubMed.26467765.s8.e0" e2="DDI-PubMed.26467765.s8.e2" /><pair ddi="false" e1="DDI-PubMed.26467765.s8.e1" e2="DDI-PubMed.26467765.s8.e1" /><pair ddi="false" e1="DDI-PubMed.26467765.s8.e1" e2="DDI-PubMed.26467765.s8.e2" /></sentence><sentence text=" In addition, in vitro accumulation of donepezil in heart tissue slices of rats was significantly increased in the presence of cilostazol"><entity charOffset="39-48" id="DDI-PubMed.26467765.s9.e0" text="donepezil" /><entity charOffset="127-137" id="DDI-PubMed.26467765.s9.e1" text="cilostazol" /><pair ddi="false" e1="DDI-PubMed.26467765.s9.e0" e2="DDI-PubMed.26467765.s9.e0" /><pair ddi="false" e1="DDI-PubMed.26467765.s9.e0" e2="DDI-PubMed.26467765.s9.e1" /></sentence><sentence text=" These results indicate that donepezil-cilostazol interaction at BCRP may be clinically relevant in heart and brain tissues"><entity charOffset="29-38" id="DDI-PubMed.26467765.s10.e0" text="donepezil" /></sentence><sentence text=" In other words, the tissue distribution of drugs can be influenced by drug-drug interaction (DDI) at efflux transporters in certain tissues (local DDI) without any apparent change in plasma concentration (systemic DDI)" /><sentence text=" " /></document>